.Attributes Medicine, Released online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antitoxin-- medicine conjugate (ADC) tisotumab vedotin led to improved progression-free and overall survival, leading to FDA approval as well as a brand new therapy possibility for people.